Due to the increasing emergence of resistant Candida spp. isolates, our group develops solid lipid nanoparticles (SLNs) that encapsulate available antifungal drugs as well as natural compounds, either individually or in combination within the same SLNs. The aim of this encapsulation in SLNs is to develop formulations with enhanced antifungal efficacy against different species and strains of Candida spp.